"We made significant progress executing on our strategic initiatives in 2022, highlighted by the expansion of our pipeline, establishing a global, transformative collaboration with Vertex focused on discovering and developing intracellular EEV-therapeutics for myotonic dystrophy type 1 and strengthening our balance sheet," said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. "We are working diligently to address FDA’s concerns regarding our IND for ENTR-601-44 and remain very confident in achieving our goal of initiating a healthy volunteer trial in 2023. Fundamentally, we believe we are well-positioned to advance our pipeline in the year ahead to create value for patients and shareholders."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TRDA:
